| 產(chǎn)品名稱 | Solcitinib - GSK 2586184 | GLPG 0778 |
| 產(chǎn)品貨號 | Axon 2539 CAS [1206163-45-2] MF C22H23N5O2MW 389.45 Purity: 98% Soluble in DMSO Description Selective JAK1 inhibitor originally developed for the treatment of systemic lupus erythematosus, psoriasis and ulcerative colitis. KEYWORDS: Solcitinib | supplier | JAK1 inhibitor | GSK 2586184 | GLPG 0778 | GSK2586184 | GLPG0778 | CAS [1206163-45-2] | JAK-STAT Pathway | JAK | Inhibitor | Janus kinase | inflammatory | lupus erythematosus | psoriasis | ulcerative colitis |
| 產(chǎn)品價(jià)格 | 現(xiàn)貨詢價(jià)，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
Solcitinib - GSK 2586184 | GLPG 0778Axon 2539 CAS [1206163-45-2] MF C22H23N5O2
DescriptionSelective JAK1 inhibitor originally developed for the treatment of systemic lupus erythematosus, psoriasis and ulcerative colitis. KEYWORDS: Solcitinib | supplier | JAK1 inhibitor | GSK 2586184 | GLPG 0778 | GSK2586184 | GLPG0778 | CAS [1206163-45-2] | JAK-STAT Pathway | JAK | Inhibitor | Janus kinase | inflammatory | lupus erythematosus | psoriasis | ulcerative colitis
Selective JAK1 inhibitor for treatment of degenerative and inflammatory diseases
Chemical nameN-(5-(4-(3,3-dimethylazetidine-1-carbonyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide Parent CAS No.[1206163-45-2] |
| 產(chǎn)品資料 |
